Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?

• Published in: BioMed research international 2014-01, Vol.2014 (2014), p.1-7
• Main Authors: Ingolf, Juhasz-Böss, Russalina, Mavrova, Simona, Moga, Julia, Radosa, Gilda, Schmidt, Bohle, Rainer M., Andrea, Hasenfus, Erich, Solomayer, Daniel, Herr
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Adult; Biomedical research; Biopsy; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cancer patients; Chemotherapy; Female; Humans; Ki-67 Antigen - metabolism; Middle Aged; Mortality; Neoadjuvant Therapy; Receptor, ErbB-2 - metabolism; Retrospective Studies; Tumors; Ultrasound imaging
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2014/628217

Background. Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant chemotherapy. Methods. This study includes patients with invasive breast cancer treated between 2008 and 2013. The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings. Results. The average Ki-67 value in our patients collectively (n=77) is 34.9 ± 24.6%. The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR. The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P=0.896). However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other. Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly. Conclusion. Our data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response.